Labcorp (LH) Competitors

Hologic (NASDAQ:HOLX) and Labcorp (NYSE:LH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Is HOLX or LH more profitable?

Hologic has a net margin of 13.83% compared to Labcorp's net margin of 5.55%. Hologic's return on equity of 19.71% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hologic	13.83%	19.71%	10.87%
Labcorp	5.55%	15.27%	6.97%

Does the media prefer HOLX or LH?

In the previous week, Labcorp had 11 more articles in the media than Hologic. MarketBeat recorded 33 mentions for Labcorp and 22 mentions for Hologic. Hologic's average media sentiment score of 1.09 beat Labcorp's score of 0.53 indicating that Hologic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hologic	13 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	9 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more risk and volatility, HOLX or LH?

Hologic has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Labcorp has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Which has preferable earnings & valuation, HOLX or LH?

Hologic has higher earnings, but lower revenue than Labcorp. Hologic is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hologic	$4.03B	3.53	$789.50M	$2.37	26.95
Labcorp	$13.01B	1.58	$746M	$8.65	28.43

Do analysts recommend HOLX or LH?

Hologic presently has a consensus target price of $77.33, indicating a potential upside of 21.08%. Labcorp has a consensus target price of $276.38, indicating a potential upside of 12.40%. Given Hologic's higher possible upside, analysts plainly believe Hologic is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hologic	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.47
Labcorp	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.57

Do institutionals & insiders believe in HOLX or LH?

94.7% of Hologic shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 1.9% of Hologic shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Hologic beats Labcorp on 9 of the 17 factors compared between the two stocks.